JP2012097105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012097105A5 JP2012097105A5 JP2011283252A JP2011283252A JP2012097105A5 JP 2012097105 A5 JP2012097105 A5 JP 2012097105A5 JP 2011283252 A JP2011283252 A JP 2011283252A JP 2011283252 A JP2011283252 A JP 2011283252A JP 2012097105 A5 JP2012097105 A5 JP 2012097105A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 239000003981 vehicle Substances 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 210000000941 bile Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000004136 fatty acid synthesis Effects 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 *C(C1(CCCCCC(CCCCCC2(CC2)C(OCc2ccccc2)=O)O)CC1)=* Chemical compound *C(C1(CCCCCC(CCCCCC2(CC2)C(OCc2ccccc2)=O)O)CC1)=* 0.000 description 4
- SODZKVKXPFZPKJ-UHFFFAOYSA-N CCNC(CCCCCC(C)(C)CO)CCCCCC1(CC1)C(O)=O Chemical compound CCNC(CCCCCC(C)(C)CO)CCCCCC1(CC1)C(O)=O SODZKVKXPFZPKJ-UHFFFAOYSA-N 0.000 description 1
- WNIZDAYISJQKHH-UHFFFAOYSA-N OC(CCCCC1(CC(Oc2ccccc2)=O)CC1)CCCCC1(CC1)C(Oc1ccccc1)=O Chemical compound OC(CCCCC1(CC(Oc2ccccc2)=O)CC1)CCCCC1(CC1)C(Oc1ccccc1)=O WNIZDAYISJQKHH-UHFFFAOYSA-N 0.000 description 1
- CPZNVSZUCNQDRP-UHFFFAOYSA-N OC(CCCCCC1(CC1)C(Oc1ccccc1)=O)CCCCCC1(CC1)C(Oc1ccccc1)=O Chemical compound OC(CCCCCC1(CC1)C(Oc1ccccc1)=O)CCCCCC1(CC1)C(Oc1ccccc1)=O CPZNVSZUCNQDRP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44179503P | 2003-01-23 | 2003-01-23 | |
| US60/441,795 | 2003-01-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004567452A Division JP4931349B2 (ja) | 2003-01-23 | 2003-12-23 | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012097105A JP2012097105A (ja) | 2012-05-24 |
| JP2012097105A5 true JP2012097105A5 (enExample) | 2012-11-22 |
| JP5593303B2 JP5593303B2 (ja) | 2014-09-17 |
Family
ID=32825172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004567452A Expired - Lifetime JP4931349B2 (ja) | 2003-01-23 | 2003-12-23 | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
| JP2011283252A Expired - Lifetime JP5593303B2 (ja) | 2003-01-23 | 2011-12-26 | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004567452A Expired - Lifetime JP4931349B2 (ja) | 2003-01-23 | 2003-12-23 | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (24) | US7335799B2 (enExample) |
| EP (3) | EP2402300B1 (enExample) |
| JP (2) | JP4931349B2 (enExample) |
| AU (1) | AU2003299993A1 (enExample) |
| BE (1) | BE2020C534I2 (enExample) |
| BR (1) | BRPI0318046B8 (enExample) |
| CA (1) | CA2513660C (enExample) |
| CY (2) | CY1119404T1 (enExample) |
| DK (1) | DK2404890T3 (enExample) |
| ES (3) | ES2594340T3 (enExample) |
| FR (1) | FR20C1041I2 (enExample) |
| HU (2) | HUE036646T2 (enExample) |
| MX (2) | MX349134B (enExample) |
| PT (1) | PT2404890T (enExample) |
| SI (1) | SI2404890T1 (enExample) |
| WO (1) | WO2004067489A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20080200453A1 (en) * | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| DK2404890T3 (en) | 2003-01-23 | 2017-10-16 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for controlling cholesterol and related uses |
| US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| WO2007016099A2 (en) * | 2005-07-29 | 2007-02-08 | Musc Foundation For Research Development | Protection of transplanted stem cells with hmg-coa reductase inhibitors |
| EP2048145B9 (en) * | 2006-08-04 | 2011-05-04 | Toyama Chemical Co., Ltd. | Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| WO2008124122A1 (en) * | 2007-04-09 | 2008-10-16 | Scidose, Llc | Combinations of statins and anti-obesity agent and glitazones |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| RU2492858C2 (ru) * | 2007-04-11 | 2013-09-20 | Омерос Корпорейшн | Композиции и способы профилактики и лечения зависимостей |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US20090137598A1 (en) | 2007-06-21 | 2009-05-28 | Veroscience, Llc | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| JP2013537240A (ja) | 2010-09-20 | 2013-09-30 | カリウス セラピューティクス エスエー | 糖尿病および脂質異常症の処置のための方法および組成物 |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| US9827222B2 (en) | 2013-07-01 | 2017-11-28 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| WO2015143276A1 (en) * | 2014-03-20 | 2015-09-24 | Esperion Therapeutics, Inc. | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders |
| CN106488987A (zh) | 2014-05-02 | 2017-03-08 | 塞勒尼斯医疗控股公司 | Hdl疗法标志物 |
| SG10201908500UA (en) * | 2015-03-13 | 2019-11-28 | Esperion Therapeutics Inc | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| CN107118098B (zh) * | 2016-02-25 | 2020-07-14 | 中国科学院上海药物研究所 | 一类脂肪酸类化合物、其制备方法及其用途 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| PL3618821T3 (pl) | 2017-01-31 | 2025-07-07 | Nephrodi Therapeutics, Inc. | Postępowanie w przypadku nerkopochodnej moczówki prostej |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| US20180338922A1 (en) | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| JP7234151B2 (ja) * | 2017-07-07 | 2023-03-07 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 脂肪酸誘導体およびこれらの使用 |
| CN109721486A (zh) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法 |
| CN111971030A (zh) | 2018-02-16 | 2020-11-20 | 艾斯柏伦治疗公司 | 贝派地酸的缓释制剂 |
| WO2019179494A1 (zh) * | 2018-03-23 | 2019-09-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的十五烷二酸化合物及药物组合物及其用途 |
| EP3666750A1 (en) | 2018-12-10 | 2020-06-17 | Sandoz AG | Crystalline form of bempedoic acid |
| KR20210110353A (ko) * | 2018-12-31 | 2021-09-07 | 루핀 리미티드 | 벰페도산의 신규한 염 및 다형 형태 |
| PH12021552553A1 (en) | 2019-04-16 | 2022-06-20 | Celagenex Res India Pvt Ltd | Synergistic lipid controlling compositions |
| AU2020296094B2 (en) | 2019-06-21 | 2025-02-06 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
| MX2022000570A (es) | 2019-07-26 | 2022-03-11 | Espervita Therapeutics Inc | Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad. |
| WO2021064166A1 (en) | 2019-10-03 | 2021-04-08 | Synthon B.V. | Crystalline forms of bempedoic acid |
| CN112679492B (zh) * | 2019-10-17 | 2022-03-18 | 中国科学院上海药物研究所 | 小檗碱衍生物、其制备方法和用途 |
| US20230036336A1 (en) | 2019-12-06 | 2023-02-02 | Synthon B.V. | Crystalline forms of sodium salt of bempedoic acid |
| CN111170855B (zh) * | 2019-12-31 | 2023-04-07 | 奥锐特药业(天津)有限公司 | 一种化合物及采用该化合物合成8-羟基-2,2,14,14-四甲基十五烷二酸的方法 |
| CN111285760B (zh) * | 2020-05-12 | 2020-08-25 | 南京佰麦生物技术有限公司 | 一种贝派地酸的合成方法及中间体 |
| WO2021255180A1 (en) | 2020-06-19 | 2021-12-23 | Synthon B.V. | Salts of bempedoic acid |
| CN111675614B (zh) * | 2020-07-14 | 2022-11-29 | 爱斯特（成都）生物制药股份有限公司 | 一种合成7-溴-2,2-二甲基庚酸乙酯的方法 |
| CN112047840A (zh) * | 2020-08-31 | 2020-12-08 | 山东药品食品职业学院 | 一种7-溴-2,2-二甲基庚酸乙酯的合成方法及合成得到的产品 |
| CN112521282A (zh) * | 2020-12-02 | 2021-03-19 | 苏州汉德创宏生化科技有限公司 | 一种贝派地酸中间体及其合成方法 |
| WO2022149161A1 (en) * | 2021-01-05 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Process for preparation of bempedoic acid and its intermediates |
| US11730712B2 (en) | 2021-01-25 | 2023-08-22 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
| KR20230152007A (ko) | 2021-01-25 | 2023-11-02 | 에스퍼비타 테라퓨틱스, 인크. | 작용화된 장쇄 카복실산, 및 질환의 치료를 위한 이의 용도 |
| CN115108904A (zh) * | 2021-03-20 | 2022-09-27 | 上海鼎雅药物化学科技有限公司 | 贝派度酸原料药的合成方法 |
| CN113233975B (zh) * | 2021-04-07 | 2023-05-23 | 海化生命(厦门)科技有限公司 | 一种贝派地酸的制备方法 |
| WO2022224962A1 (ja) | 2021-04-20 | 2022-10-27 | 興和株式会社 | 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬 |
| ES3017885T3 (en) | 2021-06-02 | 2025-05-13 | Esperion Therapeutics Inc | Compositions containing bempedoic acid alone or in combination with tolvaptan for use in a method for treating autosomal dominant polycystic kidney disease (adpkd) |
| CN115504914B (zh) * | 2021-06-23 | 2024-05-07 | 武汉武药科技有限公司 | 一种贝派地酸中间体的制备方法 |
| US20250134841A1 (en) | 2021-09-13 | 2025-05-01 | Synthon B.V. | Pharmaceutical composition of bempedoic acid |
| CN114436837B (zh) * | 2021-12-27 | 2024-02-20 | 甘李药业股份有限公司 | 一种贝派地酸中间体的纯化方法 |
| CN116120163B (zh) * | 2022-12-30 | 2024-05-28 | 安徽艾立德制药有限公司 | 一种贝派地酸的合成方法及其中间体 |
| WO2024151311A1 (en) | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| WO2024212248A1 (en) * | 2023-04-14 | 2024-10-17 | Meta Pharmaceuticals (Hk) Limited | Substituted alkanoic-diacids compound and composition and use thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
| US3441605A (en) | 1965-02-17 | 1969-04-29 | Wallace & Tiernan Inc | Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation |
| GB1196598A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Ketosebacic Acid |
| GB1196596A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a hydroxysebacic acid |
| GB1196594A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Improvements in and relating to the production of Sebacic Acid |
| FR1545224A (fr) * | 1966-12-21 | 1968-11-08 | Geigy Ag J R | Procédé de préparation de l'acide sébacique |
| GB1196597A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of an Oxido-Cyclodecene |
| GB1196595A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Lactone |
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| US4066692A (en) * | 1972-10-30 | 1978-01-03 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| IT1060366B (it) * | 1974-08-07 | 1982-07-10 | Istituto Biochimico Italiano | Acidi 19.20 bis nor prostanoici come composti ipolipemici |
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4281200A (en) * | 1979-08-30 | 1981-07-28 | The Dow Chemical Company | Catalytic process for converting oxazolidinones to their corresponding aminoalcohols |
| JPS5639033A (en) * | 1979-09-04 | 1981-04-14 | Kao Corp | Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same |
| US4518809A (en) * | 1981-06-11 | 1985-05-21 | Monsanto Company | Preparation of pentyl nonanols |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| IT1164254B (it) * | 1983-05-30 | 1987-04-08 | Luso Farmaco Inst | 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione |
| JPS59232811A (ja) * | 1983-06-16 | 1984-12-27 | Sumitomo Chem Co Ltd | 芳香族ポリアミドイミド樹脂成形体の製造方法 |
| JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US4896344A (en) * | 1984-10-15 | 1990-01-23 | Grady John K | X-ray video system |
| US4622338A (en) | 1985-03-11 | 1986-11-11 | G. D. Searle & Co. | Substituted glutaric acid lactones in the treatment of hyperlipidemia |
| US4634119A (en) * | 1985-07-11 | 1987-01-06 | Pesthy Paul K | Resilient exercise machine with body support platform |
| US4714762A (en) | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
| US5428062A (en) | 1987-01-28 | 1995-06-27 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5225439A (en) * | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US4758880A (en) | 1987-03-27 | 1988-07-19 | The Grass Valley Group, Inc. | Video matte generator |
| JP2711893B2 (ja) * | 1989-04-25 | 1998-02-10 | 長谷川香料株式会社 | ケトン類およびアルコール類 |
| JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Ｄｎａおよびその用途 |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| US5420339A (en) * | 1993-11-22 | 1995-05-30 | Warner-Lambert Company | Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors |
| JP2937012B2 (ja) * | 1994-04-08 | 1999-08-23 | 時久 増田 | 角筒包装袋の製造方法及び装置 |
| US5578639A (en) * | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| US5504073A (en) * | 1994-07-01 | 1996-04-02 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| KR0163909B1 (ko) * | 1995-09-12 | 1999-10-01 | 김광호 | 충전 형태 변환 제어형 니켈카드뮴/니켈금속수소화물 전지 충전회로 |
| JPH11515025A (ja) | 1995-11-02 | 1999-12-21 | ワーナー−ランバート・コンパニー | 脂質濃度を調節するための方法および医薬組成物 |
| GB9614991D0 (en) | 1996-07-17 | 1996-09-04 | Kverneland Kleep As | Integrated soil cultivating apparatus |
| US5807846A (en) * | 1996-11-14 | 1998-09-15 | Warner-Lambert Company | Phosphonamide ACAT inhibitors |
| IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| FR2758279B1 (fr) | 1997-01-13 | 1999-02-26 | Pechiney Recherche | Support de catalyseur a base de carbure de silicium a surface specifique elevee sous forme de granule ayant des caracteristiques mecaniques ameliorees |
| US6093744A (en) * | 1997-04-21 | 2000-07-25 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| WO1999026583A2 (en) | 1997-11-25 | 1999-06-03 | Warner-Lambert Company | Inhibtion of lipoprotein oxidation |
| ATE384035T1 (de) | 1999-04-01 | 2008-02-15 | Esperion Therapeutics Inc | Ether-verbindungen, zusammensetzungen und ihre verwendung |
| JP2001280908A (ja) * | 2000-03-29 | 2001-10-10 | Sony Precision Technology Inc | 位置検出装置 |
| IL155246A0 (en) | 2000-10-11 | 2003-11-23 | Esperion Therapeutics Inc | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| US6703422B2 (en) * | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| IL155213A0 (en) | 2000-10-11 | 2003-11-23 | Esperion Therapeutics Inc | Ketone compounds and compositions for cholesterol management and related uses |
| US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| MXPA03003021A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| NO315791B1 (no) | 2001-11-21 | 2003-10-27 | Sintef Materialteknologi | Fremgangsmåte og anordning for sammenföyning av bearbeidede metaller og legeringer |
| US7053046B2 (en) * | 2001-12-21 | 2006-05-30 | Mcgrath Kevin | Peptide activators of VEGF |
| DK2404890T3 (en) | 2003-01-23 | 2017-10-16 | Esperion Therapeutics Inc | Hydroxyl compounds and compositions for controlling cholesterol and related uses |
| US20050124887A1 (en) * | 2003-11-21 | 2005-06-09 | Koninklijke Philips Electronics N.V. | Three dimensional scan conversion of data from mechanically scanned array probes |
| US7705177B2 (en) * | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| JP4553181B2 (ja) | 2004-03-25 | 2010-09-29 | 株式会社サタケ | 残留農薬分析方法 |
| US8209479B2 (en) | 2007-07-18 | 2012-06-26 | Google Inc. | Memory circuit system and method |
-
2003
- 2003-12-23 DK DK11005303.0T patent/DK2404890T3/en active
- 2003-12-23 US US10/743,470 patent/US7335799B2/en not_active Expired - Lifetime
- 2003-12-23 SI SI200332553T patent/SI2404890T1/sl unknown
- 2003-12-23 AU AU2003299993A patent/AU2003299993A1/en not_active Abandoned
- 2003-12-23 ES ES11005304.8T patent/ES2594340T3/es not_active Expired - Lifetime
- 2003-12-23 EP EP11005304.8A patent/EP2402300B1/en not_active Expired - Lifetime
- 2003-12-23 MX MX2012007568A patent/MX349134B/es unknown
- 2003-12-23 ES ES03800258.0T patent/ES2625429T3/es not_active Expired - Lifetime
- 2003-12-23 MX MXPA05007674A patent/MXPA05007674A/es active IP Right Grant
- 2003-12-23 EP EP03800258.0A patent/EP1597223B1/en not_active Expired - Lifetime
- 2003-12-23 US US10/743,287 patent/US7119221B2/en not_active Expired - Lifetime
- 2003-12-23 US US10/743,109 patent/US7335689B2/en not_active Expired - Lifetime
- 2003-12-23 EP EP11005303.0A patent/EP2404890B1/en not_active Expired - Lifetime
- 2003-12-23 CA CA2513660A patent/CA2513660C/en not_active Expired - Lifetime
- 2003-12-23 JP JP2004567452A patent/JP4931349B2/ja not_active Expired - Lifetime
- 2003-12-23 ES ES11005303.0T patent/ES2642216T3/es not_active Expired - Lifetime
- 2003-12-23 BR BRPI0318046A patent/BRPI0318046B8/pt not_active IP Right Cessation
- 2003-12-23 HU HUE11005303A patent/HUE036646T2/hu unknown
- 2003-12-23 WO PCT/US2003/041411 patent/WO2004067489A2/en not_active Ceased
- 2003-12-23 PT PT110053030T patent/PT2404890T/pt unknown
-
2006
- 2006-06-26 US US11/426,380 patent/US7405226B2/en not_active Expired - Lifetime
-
2007
- 2007-02-28 US US11/680,105 patent/US7812199B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/928,045 patent/US7576130B2/en not_active Expired - Lifetime
-
2008
- 2008-06-09 US US12/135,504 patent/US8067466B2/en not_active Expired - Lifetime
-
2009
- 2009-06-09 US US12/481,553 patent/US7838554B2/en not_active Expired - Lifetime
-
2010
- 2010-08-27 US US12/870,184 patent/US20110003860A1/en not_active Abandoned
-
2011
- 2011-10-11 US US13/270,297 patent/US8153690B2/en not_active Expired - Lifetime
- 2011-12-26 JP JP2011283252A patent/JP5593303B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-08 US US13/414,855 patent/US8309604B2/en not_active Expired - Fee Related
- 2012-05-14 US US13/470,825 patent/US8497301B2/en not_active Expired - Fee Related
- 2012-10-12 US US13/650,852 patent/US8623915B2/en not_active Expired - Lifetime
-
2013
- 2013-06-24 US US13/925,818 patent/US9000041B2/en not_active Expired - Lifetime
- 2013-12-23 US US14/138,919 patent/US9006290B2/en not_active Expired - Lifetime
-
2015
- 2015-03-31 US US14/674,028 patent/US9624152B2/en not_active Expired - Fee Related
- 2015-03-31 US US14/674,025 patent/US9452964B2/en not_active Expired - Fee Related
-
2016
- 2016-09-23 US US15/274,436 patent/US10047028B2/en not_active Expired - Lifetime
-
2017
- 2017-04-14 US US15/487,623 patent/US10118881B2/en not_active Expired - Lifetime
- 2017-09-26 CY CY20171101011T patent/CY1119404T1/el unknown
-
2018
- 2018-04-11 US US15/950,608 patent/US20190084908A1/en not_active Abandoned
- 2018-09-26 US US16/142,547 patent/US10941095B2/en not_active Expired - Fee Related
-
2019
- 2019-07-23 US US16/519,767 patent/US20200189999A1/en not_active Abandoned
-
2020
- 2020-08-26 HU HUS2000033C patent/HUS2000033I1/hu unknown
- 2020-08-28 CY CY2020031C patent/CY2020031I2/el unknown
- 2020-08-28 FR FR20C1041C patent/FR20C1041I2/fr active Active
- 2020-09-08 BE BE2020C534C patent/BE2020C534I2/fr unknown
-
2021
- 2021-02-01 US US17/163,810 patent/US20210395175A1/en not_active Abandoned
-
2022
- 2022-08-03 US US17/880,023 patent/US20230210800A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012097105A5 (enExample) | ||
| RU2014136085A (ru) | Окисленные соединения липидов и их применение | |
| JP2018536710A5 (enExample) | ||
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| JP2007508361A5 (enExample) | ||
| JP2015517579A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| CA2798259A1 (en) | Nuclear receptor binding agents | |
| CA2861643A1 (en) | Methods of reducing risk of cardiovascular disease | |
| JP2013513613A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| JP2013509411A5 (enExample) | ||
| JP2012507577A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| JP2014503560A5 (enExample) | ||
| RU2009145541A (ru) | Терапевтические соединения | |
| RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
| BR112013028095A2 (pt) | inibidores de csf-1r para o tratamento de tumores cerebrais | |
| HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
| JP2013519653A5 (enExample) | ||
| CO6771414A2 (es) | Métodos de tratamiento usando compuestos lípidos | |
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
| JP2014505017A5 (enExample) | ||
| JP2011046708A5 (enExample) |